2Corsetti JP, Rainwater DL, Moss AJ, et al. High lipoprotein- associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarcfion patients. Clin Chem, 2006, 52: 1331- 1338.
3Brilakis ES, McConnell JP, Lennon RJ, et al. Association of lipoprotein-associated phospholipase .A_2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J,2005,26: 137- 144.
4Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies : Part II. Circulation,2003,108 : 1772-1778.
5de Korte CL, Sierevogel MJ, Mastik F, et al. Identification of atherosclerotic plaque components with intravascular ultrasound elastography in vivo: a Yucatan pig study. Circulation, 2002, 105 : 1627-1630.
6Winklcr K, Winkclmarm BR, Scharnagl H, et al. Platelet- activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation,2005,111:980-987.
7Packard CJ, O' Reilly DS, Caslake MJ, et al. Lipoprotein- associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med, 2000, 343:1148-1155.
8BaUantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein- associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation ,2004,109:837-842.
9Koenig W, Khuseyinova N, Lowel H, et al. Lipoprotein- associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middleaged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation, 2004,110 : 1903-1908.
10Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein- associated phosphohpase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation, 2005, 111:570-575.
5Marshall AC,Peter HJ,Michael HD. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker [J]. The American Journal of Cardiolody, 2005,101 ( 12 ) : 42-50.
6Barber M ,Stott DJ,Langhorne P.An internationally agreed defini- tion of progressing stroke[J].Cerebrovase Dis, 2004,18 : 225-226.
7Sumer M,Ozdemir l,Erturk O.Progression in acute ischemic strok frequency,risk factors and prognosis[J].J Clin Neurosci,2003,24: 178-180.
